DuRoss Amy's Form 4 filing
Biolife Solutions Inc (BLFS) · filed Mar 20, 2025
- Accession no.
- 0001628280-25-014192
- Filed
- Mar 20, 2025
- Trade date
- Mar 14-18, 2025
- Filing delay
- 6 daysLate
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $140.6K. It was filed 6 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| DuRoss AmyCIK 0001854968 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.18 to $25.91, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.
- F3
The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the first anniversary of the measurement date of 01-02-2025.
Referenced by the price of 1 transaction in Table I.